Mirati Therapeutics receives MHRA approval for KRAZATI

Mirati Therapeutics announced the United Kingdom’s Medicines and Healthcare Products Regulatory Agency granted conditional marketing authorization approval for KRAZATI as a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer with KRAS mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy. “KRAZATI offers a compelling therapeutic option for patients with previously treated locally advanced NSCLC with a KRASG12C mutation. MHRA’s authorization is a significant step towards improving the options available for patients and clinicians in Great Britain,” said Alan Sandler, M.D., chief medical officer, Mirati Therapeutics, Inc. “We are encouraged by the opportunity to bring KRAZATI, a potential best-in-class treatment to qualified patients.”